+ More
Technology
Collaborations
 News Room
 Contact Us
Home \ Diabetes Care Market

Diabetes prevalence is growing at a staggering pace

The Risk of Not Knowing

It is important for people with diabetes to manage blood sugars and avoid high glycemic levels (hyperglycemia) to avoid dangerous and debilitating long term conditions including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental diseases, pregnancy complications, sexual dysfunction, and nervous system disease (1). It is also crucial to avoid dangerously low glycemic levels (hypoglycemia), which are associated with acute cognitive dysfunctions like blurred vision, irritability, dizziness, and even loss of consciousness or death.

Current treatments, which are based on conventional self monitoring blood glucose (SMBG) methods, only approximate the function of the normal pancreas and the blood glucose profiles of even the most diligent individuals can remain markedly abnormal. Studies of glycemic variability indicate that evenbrief hyper- and hypoglycemia may have profound detrimental effects. Without the means for reliable, convenient continuous glucose monitoring needed to optimize care, many individuals may experience periods of hyperglycemia and hypoglycemia, increasing both short term and long term health risks. Patients and caregivers face a delicate balancing act to maintain glycemic control. A constant dilemma is that their efforts to prevent complications by avoiding hyperglycemia can increase the risk for dangerous hypoglycemia. The GlySens ICGM system is intended to help alleviate the worries that can accompany such efforts to improve glucose control.
Learn about the Product

Continuous Glucose Monitoring is Knowledge

A 2008 major clinical trial funded by the Juvenile Diabetes Research Foundation concluded that patients using continuous glucose monitoring devices experienced significant improvements in glucose control. Over the long term, this improvement in control is expected to lower the risk of debilitating complications.(2,3)

But not everyone with insulin-dependent diabetes uses a CGM, because currently available CGM products have significant drawbacks:
They're short term
Current “needle-sensor” products last for up to 7 days before requiring removal and reinsertion of a new sensor. In contrast, the GlySens fully implanted sensor requires only a brief outpatient insertion and is designed to last for up to 1-year without user intervention. Thus freeing individuals to worry less about their diabetes devices.
They impact body image
Through-the-skin and on-the-skin components are viewed by many as problematic for daily as well as active lifestyles.  In contrast, the GlySens sensor is fully implanted designed to eliminate the visible body burden of CGM technology and enable individuals to live their healthiest and uncompromised life.
They need daily calibration
Commercially available products require daily recalibration by self monitored blood glucose measurement (SMBG) during use to maintain operation.  On the contrary, the GlySens system is intended to require once or twice per month recalibration by SMBG. This is designed to reduce the burden of diabetes care.

The GlySens ICGM system is designed to shift the paradigm in blood glucose management

Conventional “fingerstick” monitoring, while offering none of the advantages of continuous approaches, has estimated worldwide expenditures of $7 to $10 billion dollars. Even with the numerous limitations of current “needle-sensor” CGM products, growing interest and reimbursement confirms the market appetite for a more user-centric and acceptable CGM. What’s more, millions of people today with other chronic conditions are enjoying life with the use of implantable medical technologies, and the robust U.S. implantable device market is expected to grow to $74 billion by 2018. (4)

Because the GlySens ICGM system is designed to enable long term continuous monitoring with nothing worn on the skin, and with only minimal need for device interaction, it is expected that it will offer people living with diabetes a new level of empowerment to take better care of their health.
Citations

1. Centers for Disease Control and Prevention. “National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014.” Atlanta, GA: U.S. Department of Health and Human Services; 2014
2. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes.” The New England Journal of Medicine. 359. 2008.
3. “JDRF Funded Clinical Trial Demonstrates Continuous Glucose Monitoring Improves Blood Sugar Control.” Juvenile Diabetes Research Foundation. September 2008.
4. Transparency Market Research. “Implantable Medical Devices Market (Reconstructive Joint Replacement, Spinal Implants, Cardiovascular Implants, Dental Implants, Intraocular Lens and Breast Implants) U.S. Industry Analysis, Size, Share, Trends,  Growth and Forecast 2012-2018,” published 1/23/13.
3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121
Ph:  +1 (858) 638-7708
Fax: +1 (858) 638-7727

TechnologyNews RoomCareersContact Us

© 2017 GlySens Incorporated. All Rights Reserved.
Caution - INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.
GlySens®, Eclipse®, and ICGM® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
 Terms of Use Privacy Policy
map-markercogsphonelinkedinslidesharenewspaper-omagic-wandmenu